Todd Triplett

Todd Triplett serves as Assistant Professor in the Department of Immunotherapeutics and Biotechnology at Texas Tech University Health Sciences Center's School of Pharmacy, where his research integrates immunology and oncology to address cancer mechanisms and immune responses.

Education:

• PhD in Immunology, Oregon Health and Science University (2012)
• BS in Biology, St. Edward's University (2006)

His work centers on cancer immunotherapy, particularly T-cell acute lymphoblastic leukemia (T-ALL) and solid tumors, with significant contributions to understanding IDO-mediated immune suppression and kynurenine pathway dynamics. Recent research extends to infectious disease immunology, analyzing longitudinal immune trajectories in COVID-19 patients through the IMPACC consortium, and investigating myeloid cell roles in tumor microenvironments.

Publication trends (2020-2024) reveal concentrated efforts in translational applications: HDAC inhibitors (bocodepsin) for immunotherapy combinations, immune checkpoint blockade in gastrointestinal cancers, and mechanistic studies of viral immune responses. These reflect multi-institutional collaborations focused on clinical translation.

Scientific Awards:

• No major awards documented in current profile

While specific advising relationships or grant details are unlisted, his involvement in first-in-human clinical trials (e.g., bocodepsin) and large consortia like IMPACC indicates active grant-supported research. Collaborative networks span cancer immunology and pandemic response initiatives.

Dr. Triplett participates in cross-institutional teams including the IMPACC study for SARS-CoV-2 research and TTUHSC-based groups developing novel immunotherapies, with recent work emphasizing rational drug combinations for solid tumors and leukemia.